Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2011-02-25 Major Shareholding Noti…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2011
Major Shareholding Notification Classification · 99% confidence The document explicitly details changes in shareholding ('Before the transaction', 'After the transaction', 'Resulting distribution of total holdings') for a specific holder (FMR LLC) in an issuer (Medivir Aktiebolag). It mentions 'Reason for major shareholding notification Buy' and provides specific percentages and share counts. This content directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The document is a direct report of the change, not an announcement of a report's publication.
2011-02-25 English
Earnings Release 2010
Earnings Release Classification · 99% confidence The document is titled "Bokslutskommuniké 1 januari – 31 december 2010" (Year-end report/Financial Statement Release for January 1 – December 31, 2010). It contains detailed financial summaries for the full year 2010 and the fourth quarter, including net sales, net result, EPS, and cash flow. It also discusses significant business developments (Hepatitis C trials, financing activities, new agreements) and provides forward-looking statements and details about an upcoming conference call to discuss the report. This structure strongly indicates a comprehensive annual financial disclosure, which aligns best with the Annual Report (10-K) definition, although it is presented as a 'Bokslutskommuniké' (Year-end report) which is the local equivalent of a 10-K summary or the primary annual filing in many jurisdictions. Given the depth of financial data and the full-year scope, 10-K is the most appropriate classification among the provided options, rather than a brief Earnings Release (ER) or an Interim Report (IR). FY 2010
2011-02-22 Swedish
Audit Report / Information 2010
Audit Report / Information Classification · 98% confidence The document is explicitly titled "Financial Statement, 1 January – 31 December 2010" and contains detailed financial highlights for the full year 2010, including net sales, profit/loss, cash flow, and balance sheet figures (cash equivalents). It also includes operational highlights, management commentary, and subsequent events related to clinical trials and financing activities. This structure and content strongly indicate a comprehensive annual financial report. Although it is presented as a 'Press Release' and mentions a conference call, the core content is the full-year financial performance data, which aligns best with the Annual Report (10-K) definition, even if the specific regulatory filing format (like the US SEC 10-K) is not explicitly named, as it covers the full fiscal year performance. FY 2010
2011-02-22 English
Medivir Announces positive Phase 2b 48-week (SVR24) Interim Results of TMC435 in Treatment-naïve Patients
Earnings Release Classification · 99% confidence The document is explicitly titled "Press Release" and announces "positive Phase 2b 48-week (SVR24) Interim Results of TMC435". It details clinical trial efficacy and safety data, concluding with information about an upcoming conference call for analysts and investors to discuss the announcement. This structure—a brief announcement of key financial/operational results followed by details and a call invitation—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript (CT). Since it is the initial announcement of period results (even if clinical trial results rather than quarterly financials), ER is the most appropriate classification. FY 2011
2011-02-22 English
Medivir offentliggör positiva interimsresultat (SVR24) från fas 2b-studie omfattande 48 veckors behandling med TMC435 på behandlingsnaiva patienter
Earnings Release Classification · 98% confidence The document is a press release dated February 22, 2011, announcing positive interim results (SVR24) from a Phase 2b clinical study (PILLAR) for the drug TMC435 in treating chronic Hepatitis C. It details efficacy data (SVR4, SVR24 rates) and safety profiles, and concludes by announcing a conference call for investors and analysts to discuss these results. This content—a detailed announcement of specific, periodic financial/clinical performance data (interim results)—fits the definition of an Earnings Release (ER) or potentially an Interim Report (IR) if it were comprehensive. However, since it is a press release focused on key results and immediately followed by an announcement of a conference call to discuss them, it strongly aligns with the 'initial announcement of quarterly/periodical financial results (key highlights only)' definition, which is 'ER'. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), but rather the initial highlight release. FY 2011
2011-02-22 Swedish
The phase 3 program for TMC435 in treatment-naïve patients and patients who have relapsed after prior interferon-based treatment has now started
Regulatory Filings Classification · 92% confidence The document is explicitly titled as a "Press Release" dated February 18, 2011, announcing that the Phase 3 clinical trials for the drug TMC435 have started. It details the structure of these trials (QUEST-1, QUEST-2, PROMISE) and includes statements from the CEOs/VPs of Medivir and Tibotec. This content is characteristic of an initial announcement regarding clinical trial progression or a significant corporate event, which is best classified as an Earnings Release (ER) if it contains material financial/operational news, or potentially a Regulatory Filing (RNS) if it's a general announcement. Since it details a major operational milestone (start of Phase 3 trials) and mentions a financial milestone recognition, it functions as a key operational update. However, it is not a formal financial report (10-K, IR, MRQ) nor a presentation (IP). Given the format (Press Release) and the nature of the announcement (major operational/development update), it fits best under the general category for significant corporate news announcements that aren't strictly financial reports or specific regulatory disclosures. In the absence of a specific 'Clinical Trial Update' code, 'ER' (Earnings Release, often used for major operational news releases) or 'RNS' (Regulatory Filings/General Announcement) are the closest fits. Since it is a press release announcing a major development milestone, 'ER' is often used for such announcements when they are not quarterly results, but 'RNS' is the safest fallback for non-standard announcements. Given the context of a press release announcing a major development milestone, I will classify it as a general Regulatory Filing (RNS) as it is a broad announcement not covered by the more specific financial or meeting codes.
2011-02-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.